Yazar "Atcı, Muhammed Mustafa" için listeleme
-
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)
Şenocak Taşçı, Elif; Oyan, Başak; Sönmez, Özlem; Mutlu, Arda Ulaş; Atcı, Muhammed Mustafa; Sakin, Abdullah; Öner, İrem; Yeşil Çınkır, Havva; Karakurt Eryılmaz, Melek; Çağlayan, Dilek; Yazdan Balçık, Onur; Paksoy, Nail; Bozkurt, Mustafa (BioMed Central Ltd, 2024)Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated ... -
Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study
Atcı, Muhammed Mustafa; Akagündüz, Baran; Demir, Metin; Dönmez Yılmaz, Binnur; Akın Telli, Tuğba; Can, Orçun; Çil, İbrahim; Göktaş Aydın, Sabin; Özyurt, Neslihan; Önder, Arif Hakan; Selvi, Oğuzhan; Sakin, Abdullah (NLM (Medline), 2022)INTRODUCTION: A significant proportion of cervical cancer (CC) patients are diagnosed at a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the cornerstone of treatment for patients with locally advanced CC. ... -
The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors
Göktaş Aydın, Sabin; Çakan Demirel, Burçin; Bilici, Ahmet; Yılmaz, Cansu; Topçu, Atakan; Aykan, Musa Barış; Kahraman, Seda; Atcı, Muhammed Mustafa; Akbıyık, Ilgın; Akgül, Fahri; Ölmez, Ömer Fatih; Aydın, Ahmet (Ankara Hematology Oncology Association, 2023)Introduction: There is a lack of evidence of the outcomes in elderly patients advanced stage biliary tract cancer due to the patients aged over 65 years are less than 25% in many prospective trials. We designed a retrospective ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...